| Autor: |
Rittershaus CW; AVANT Immunotherapeutics, Inc, Needham, MA 02494, USA. crittershaus@avantimmune.com, Miller DP, Thomas LJ, Picard MD, Honan CM, Emmett CD, Pettey CL, Adari H, Hammond RA, Beattie DT, Callow AD, Marsh HC, Ryan US |
| Jazyk: |
angličtina |
| Zdroj: |
Arteriosclerosis, thrombosis, and vascular biology [Arterioscler Thromb Vasc Biol] 2000 Sep; Vol. 20 (9), pp. 2106-12. |
| DOI: |
10.1161/01.atv.20.9.2106 |
| Abstrakt: |
Using a vaccine approach, we immunized New Zealand White rabbits with a peptide containing a region of cholesteryl ester transfer protein (CETP) known to be required for neutral lipid transfer function. These rabbits had significantly reduced plasma CETP activity and an altered lipoprotein profile. In a cholesterol-fed rabbit model of atherosclerosis, the fraction of plasma cholesterol in HDL was 42% higher and the fraction of plasma cholesterol in LDL was 24% lower in the CETP-vaccinated group than in the control-vaccinated group. Moreover, the percentage of the aorta surface exhibiting atherosclerotic lesion was 39.6% smaller in the CETP-vaccinated rabbits than in controls. The data reported here demonstrate that CETP activity can be reduced in vivo by vaccination with a peptide derived from CETP and support the concept that inhibition of CETP activity in vivo can be antiatherogenic. In addition, these studies suggest that vaccination against a self-antigen is a viable therapeutic strategy for disease management. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
